B G Redman

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Kidney cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1072-81. 2006
  2. ncbi Sunitinib efficacy against advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:1883-7. 2007
  3. ncbi Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    John A Thompson
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:2034-9. 2008
  4. ncbi Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
    B G Redman
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, Detroit, MI, USA
    J Clin Oncol 16:1844-8. 1998
  5. ncbi Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer
    Bruce G Redman
    Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor 48109 0948, USA
    Clin Cancer Res 9:1666-72. 2003
  6. ncbi Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
    Bruce G Redman
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    J Immunother 31:591-8. 2008
  7. ncbi Supportive care, pain management, and quality of life in advanced prostate cancer
    P Esper
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    Urol Clin North Am 26:375-89. 1999
  8. ncbi A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer
    Alfred E Chang
    Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109 0932, USA
    Clin Cancer Res 8:1021-32. 2002
  9. ncbi Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer
    Alfred E Chang
    Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 21:884-90. 2003
  10. ncbi Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group
    Vernon K Sondak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 20:2058-66. 2002

Research Grants

  1. T CELL THERAPY OF HUMAN RENAL CELL CANCER
    Bruce Redman; Fiscal Year: 2002

Detail Information

Publications17

  1. ncbi Kidney cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1072-81. 2006
  2. ncbi Sunitinib efficacy against advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:1883-7. 2007
    ..We assessed the efficacy of the oral multitargeted tyrosine kinase inhibitor sunitinib in patients with metastatic clear cell renal cell carcinoma...
  3. ncbi Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    John A Thompson
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:2034-9. 2008
    ....
  4. ncbi Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
    B G Redman
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, Detroit, MI, USA
    J Clin Oncol 16:1844-8. 1998
    ..Both paclitaxel and carboplatin have single-agent activity against carcinoma of the urothelium. We evaluated the combination of paclitaxel and carboplatin in the treatment of advanced cancers of the urothelium...
  5. ncbi Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer
    Bruce G Redman
    Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor 48109 0948, USA
    Clin Cancer Res 9:1666-72. 2003
    ..Tetrathiomolybdate (TM), a copper-lowering agent, has been shown in preclinical murine tumor models to be antiangiogenic. We evaluated the antitumor activity of TM in patients with advanced kidney cancer in a Phase II trial...
  6. ncbi Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
    Bruce G Redman
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    J Immunother 31:591-8. 2008
    ..No clinical responses were seen. Autologous tumor lysate-pulsed DC vaccine with or without IL-2 was well tolerated and immunogenic but failed to induce clinical response in patients with advanced melanoma...
  7. ncbi Supportive care, pain management, and quality of life in advanced prostate cancer
    P Esper
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    Urol Clin North Am 26:375-89. 1999
    ..Close attention to what patients tell us about their care will make the challenge more attainable and the caregiving more satisfying...
  8. ncbi A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer
    Alfred E Chang
    Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109 0932, USA
    Clin Cancer Res 8:1021-32. 2002
    ..The objectives of this study were to assess the toxicity and immunological response induced by the intradermal (i.d) administration of tumor lysate-pulsed dendritic cells (DCs)...
  9. ncbi Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer
    Alfred E Chang
    Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 21:884-90. 2003
    ..Previous preclinical and clinical studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reactive T cells in draining lymph nodes. The adoptive transfer of these cells can result in tumor regression...
  10. ncbi Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group
    Vernon K Sondak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 20:2058-66. 2002
    ..Future investigations of adjuvant vaccine approaches for patients with intermediate-thickness melanoma should involve larger numbers of patients and ideally should include sentinel node biopsy staging...
  11. ncbi Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma
    Timothy S Wang
    Department of Dermatology, University of Michigan Health System, University of Michigan Comprehensive Cancer Center, USA
    J Am Acad Dermatol 51:399-405. 2004
    ....
  12. ncbi Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses
    Takekazu Iuchi
    Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI 48109 0666, USA
    Cancer Res 68:4431-41. 2008
    ..Collectively, these findings provide a rationale to evaluate the use of IL-21 in T-cell therapy of human cancers...
  13. ncbi Immunotherapy of kidney cancer
    Petros D Grivas
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, USA
    Curr Clin Pharmacol 6:151-63. 2011
    ..At the post-genomic era, the development of novel biomarkers can contribute to more accurate patient selection, resulting in higher responses and less toxicity of immunotherapeutic approaches...
  14. ncbi Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
    ..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)...
  15. ncbi Sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 295:2516-24. 2006
    ..Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients...
  16. ncbi The times they are a-changin' (Bob Dylan, 1964)
    Deborah A Bradley
    Cancer 110:2366-9. 2007
  17. ncbi Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:16-24. 2006
    ..SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC...

Research Grants2

  1. T CELL THERAPY OF HUMAN RENAL CELL CANCER
    Bruce Redman; Fiscal Year: 2002
    ..Lloyd Stoolman. Dr. Stoolman plans to examine novel methods to enrich tumor reactive lymphoid cells based upon adhesion marker expansion utilizing samples generated from this proposal. ..